Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 2 of 2: Calculated dose response metrics - Dataset (ID:20344)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Primary Target | Pathway | GR50 | GRmax | GR_AOC | Death_AUC | GR Hill Coefficient | GEC50 | GR r2 |
---|---|---|---|---|---|---|---|---|---|---|
SK-BR-3 | TGX221 | PI3Kb | PI3K/mTOR | Inf | 0.7496 | -0.0084 | 0.0076 | 4.9846 | 4.3561 | 0.86723 |
HCC1954 | A-1210477 | Mcl-1 | Misc | Inf | 0.8844 | -0.0259 | 0.0076 | 0.0000 | Inf | 0.43063 |
HCC1428 | Saracatinib | SRC | MAPK/nRTK | Inf | 0.6691 | 0.0697 | 0.0076 | 0.8735 | 1.6565 | 0.94133 |
SUM149PT | Alpelisib | PI3Ka | PI3K/mTOR | Inf | 0.8446 | 0.0387 | 0.0076 | 0.5903 | 8.2866 | 0.80431 |
T47D | Palbociclib | CDK4/6 | Cell cycle | 0.027507 | 0.1166 | 0.4501 | 0.0077 | 1.5536 | 0.022367 | 0.99262 |
HME1 | Pictilisib | pan PI3K | PI3K/mTOR | 2.8093 | 0.1260 | 0.1418 | 0.0078 | 1.0287 | 3.8551 | 0.98326 |
CAL-120 | Saracatinib | SRC | MAPK/nRTK | 15.6396 | 0.5261 | 0.1730 | 0.0078 | 0.3429 | 33.0327 | 0.96689 |
HME1 | Ipatasertib | AKT | PI3K/mTOR | Inf | 0.6353 | 0.0365 | 0.0079 | 1.2722 | 3.6876 | 0.93611 |
HME1 | Alpelisib | PI3Ka | PI3K/mTOR | 6.0356 | 0.3071 | 0.1123 | 0.0079 | 0.9018 | 20.4027 | 0.98253 |
HCC1500 | A-1210477 | Mcl-1 | Misc | Inf | 0.8719 | -0.0368 | 0.0081 | 0.0000 | Inf | 0.32761 |
T47D | ABT-737 | Bcl2/XL | Misc | 12.2023 | 0.5888 | 0.0010 | 0.0084 | 2.2890 | 9.7541 | 0.92156 |
HCC1500 | Olaparib | PARP | Misc | 6.3506 | 0.2744 | 0.0985 | 0.0084 | 1.0887 | 17.4212 | 0.94589 |
MDA-MB-231 | Cisplatin | Chemo | Chemotherapy | 2.415 | 0.2721 | 0.1500 | 0.0084 | 1.6944 | 1.6486 | 0.99899 |
SUM159PT | Cediranib | VEGFR/cKIT | RTK | 8.1187 | 0.3173 | 0.0491 | 0.0085 | 2.1882 | 12.8042 | 0.99762 |
HCC1937 | Alpelisib | PI3Ka | PI3K/mTOR | 18.8171 | 0.6577 | 0.0501 | 0.0085 | 0.8078 | 73.2808 | 0.94623 |
HCC1806 | Palbociclib | CDK4/6 | Cell cycle | Inf | 0.6924 | 0.1460 | 0.0085 | 1.6543 | 0.024125 | 0.93749 |
HCC1419 | Cisplatin | Chemo | Chemotherapy | 1.7988 | 0.0949 | 0.2293 | 0.0086 | 1.0769 | 2.0814 | 0.93793 |
T47D | Dasatinib | BCR/ABL | MAPK/nRTK | 12.5697 | 0.4961 | 0.1933 | 0.0086 | 0.2753 | 679.7315 | 0.95229 |
BT-20 | Olaparib | PARP | Misc | 15.2735 | 0.6064 | 0.0657 | 0.0087 | 0.8235 | 57.982 | 0.94742 |
T47D | Saracatinib | SRC | MAPK/nRTK | 3.9647 | 0.3892 | 0.1722 | 0.0087 | 0.6928 | 1.6318 | 0.9752 |
HCC1395 | Alpelisib | PI3Ka | PI3K/mTOR | 14.2707 | 0.6375 | 0.0319 | 0.0088 | 1.2066 | 35.4714 | 0.90001 |
HCC1428 | Olaparib | PARP | Misc | 0.55326 | 0.1185 | 0.3229 | 0.0089 | 0.8769 | 0.48774 | 0.98952 |
SUM149PT | PF-4708671 | p70S6K | PI3K/mTOR | 20.5582 | 0.7287 | 0.0241 | 0.0090 | 1.0700 | 53.3219 | 0.95776 |
CAMA-1 | Cabozantinib | VEGFR2/MET | RTK | 8.7107 | 0.2436 | 0.0342 | 0.0090 | 4.9963 | 10.1282 | 0.97965 |
CAL-51 | ABT-737 | Bcl2/XL | Misc | 30.4739 | 0.8756 | 0.0125 | 0.0091 | 1.7501 | 30.7264 | 0.93007 |